Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119:S30–5.
Carandang F, Anglemyer A, Longhurst CA, et al. Association between maintenance fluid tonicity and hospital-acquired hyponatremia. J Pediatr. 2013;163:1646–51. This study evaluated over 1,000 hospitalized children with a normal serum sodium receiving intravenous fluids. It demonstrated that 35% of patients developed hyponatremia, with hypotonic intravenous fluid administration an independent risk factor for developing hyponatremia.
Gankam-Kengne F, Ayers C, Khera A, de Lemos J, Maalouf NM. Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. Kidney Int. 2013;83:700–6.
Mohan S, Gu S, Parikh A, Radhakrishnan J. Prevalence of hyponatremia and association with mortality: results from NHANES. Am J Med. 2013;126:1127–37 e1.
Moritz ML, Carlos AJ. Hospital-acquired hyponatremia–why are hypotonic parenteral fluids still being used? Nat Clin Pract Nephrol. 2007;3:374–82.
Chung HM, Kluge R, Schrier RW, Anderson RJ. Postoperative hyponatremia. A prospective study. Arch Intern Med. 1986;146:333–6.
Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis. 2013;62:139–49.
Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One. 2013;8:e80451.
Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71 e1–8. This case-control study found that over 20% of hyponatremic patients presenting to the emergency department had fractures. It further demonstrated that mild chronic hyponatremia produced gait disturbance and cognitivie impairment, which may be the reason for falls.
Ayus JC, Moritz ML. Bone disease as a new complication of hyponatremia: moving beyond brain injury. Clin J Am Soc Nephrol. 2010;5:167–8.
Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol. 2010;5:275–80. This study demonstrated that hyponatremia was an independent risk factor for fracture occurrence in a cohort of over 1,000 women who had undergone bone mineral density studies.
Verbalis JG, Barsony J, Sugimura Y, et al. Hyponatremia-induced osteoporosis. J Bone Miner Res. 2010;25:554–63.
Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML. Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant. 2012;27:3725–31.
Amin A, Deitelzweig S, Christian R, et al. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J Hosp Med Off Publ Soc Hosp Med. 2012;7:634–9.
van der Meer JW, Netea MG. A salty taste to autoimmunity. N Engl J Med. 2013;368:2520–1.
Mandai S, Kuwahara M, Kasagi Y, et al. Lower serum sodium level predicts higher risk of infection-related hospitalization in maintenance hemodialysis patients: an observational cohort study. BMC Nephrol. 2013;14:276.
Barlow ED, De Wardener HE. Compulsive water drinking. Q J Med. 1959;28:235–58.
Oksche A, Rosenthal W. The molecular basis of nephrogenic diabetes insipidus. J Mol Med. 1998;76:326–37.
Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest. 1973;52:3212–9.
Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med. 1967;42:790–806.
Schwartz WB, Bennet W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529–42.
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–72.
Decaux G, Musch W. Clinical laboratory evaluation of the syndrome of inappropriate secretion of antidiuretic hormone. Clin J Am Soc Nephrol. 2008;3:1175–84.
Maesaka JK, Miyawaki N, Palaia T, Fishbane S, Durham JH. Renal salt wasting without cerebral disease: diagnostic value of urate determinations in hyponatremia. Kidney Int. 2007;71:822–6.
Olsson K, Ohlin B, Melander O. Epidemiology and characteristics of hyponatremia in the emergency department. Eur J Intern Med. 2013;24:110–6.
Leaf A, Bartter FC, Santos RF, Wrong O. Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest. 1953;32:868–78.
Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med. 2006;119:S36–42.
Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM. 1998;91:749–53.
Adrogue HJ, Madias NE. Aiding fluid prescription for the dysnatremias. Intensive Care Med. 1997;23:309–16.
Pham PC, Chen PV, Pham PT. Overcorrection of hyponatremia: where do we go wrong? Am J Kidney Dis. 2000;36:E12.
Sandhu G, Zouain E, Chan G. Caution of overdependence on formulas while treating hyponatremia. Am J Emerg Med. 2012;30:1659 e5–6.
Moritz ML, Ayus JC. Prevention of Hospital-Acquired Hyponatremia: Do We Have the Answers? Pediatrics. 2011.
Moritz ML, Ayus JC. Prevention of hospital-acquired hyponatremia: a case for using isotonic saline. Pediatrics. 2003;111:227–30. This review explains why hypotonic fluid administration is a primary culprit in the development of both hospital-acquired hyponatremia and hyponatremic encephalopathy, and the rationale for administering isotonic fluids for the prevention of hyponatremia.
Foster BA, Tom D, Hill V. Hypotonic versus Isotonic Fluids in Hospitalized Children: A Systematic Review and Meta-Analysis. J Pediatr 2014. This study is a meta-analysis of 10 prospective studies including almost 1,000 children, demonstrating that hypotonic fluids, in comparison to normal saline, were associated with a 6.1 relative risk for developing moderate hyponatremia.
Wang J, Xu E, Xiao Y. Isotonic Versus Hypotonic Maintenance IV Fluids in Hospitalized Children: A Meta-Analysis. Pediatrics. 2014;133:105–13.
Padhi S, Bullock I, Li L, Stroud M. Intravenous fluid therapy for adults in hospital: summary of NICE guidance. BMJ. 2013;347:f7073.
Williams CN, Belzer JS, Riva-Cambrin J, Presson AP, Bratton SL. The incidence of postoperative hyponatremia and associated neurological sequelae in children with intracranial neoplasms. J Neurosurg Pediatr. 2014;13:283–90.
Pemde HK, Dutta AK, Sodani R, Mishra K. Isotonic Intravenous Maintenance Fluid Reduces Hospital Acquired Hyponatremia in Young Children with Central Nervous System Infections. Indian journal of pediatrics 2014.
Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med. 1992;117:891–7. This study demonstrated that female gender was associated with a relative risk of almost 30 for death or permanent neurologic impairment from hyponatremic encephalopathy.
Ayus JC, Achinger SG, Arieff A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia. Am J Physiol Renal Physiol. 2008;295:F619–24.
Arieff AI, Kozniewska E, Roberts TP, Vexler ZS, Ayus JC, Kucharczyk J. Age, gender, and vasopressin affect survival and brain adaptation in rats with metabolic encephalopathy. Am J Physiol. 1995;268:R1143–52.
Norenberg MD, Papendick RE. Chronicity of hyponatremia as a factor in experimental myelinolysis. Ann Neurol. 1984;15:544–7.
Arieff AI, Ayus JC, Fraser CL. Hyponatraemia and death or permanent brain damage in healthy children. BMJ. 1992;304:1218–22.
Ayus JC, Armstrong D, Arieff AI. Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int. 2006;69:1319–25.
Moritz ML, Ayus JC. New aspects in the pathogenesis, prevention, and treatment of hyponatremic encephalopathy in children. Pediatr Nephrol. 2010;25:1225–38.
Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA. 1999;281:2299–304. A prospective study demonstrating high morbidity and mortality associated with fluid restriction for the treatment of chronic hyponatremic encephalopathy, and that orthapedic injury could be the presenting feature of chronic hyponatremic encephalopathy in the elderly.
Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med. 2000;132:711–4. This study demonstrated that pulmonary edema could be the presenting manifestation of hyponatremic encephalopathy in otherwise healthy young females, and that the condition rapidly reversed following treatment with hypertonic saline.
Sundgren PC, Reinstrup P, Romner B, Holtas S, Maly P. Value of conventional, and diffusion- and perfusion weighted MRI in the management of patients with unclear cerebral pathology, admitted to the intensive care unit. Neuroradiology. 2002;44:674–80.
Moritz ML, Ayus JC. 100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy. Metab Brain Dis. 2010;25:91–6. A review that explains in detail how hypertonic saline can be used safely and effectively to treat hyponatremic encephalopathy.
Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126:S1–42.
Spasovski G, Vanholder R, Allolio B, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014. A comprehensive review on the evaluation and management of hyponatremia put together by the European Society of Intensive Care Medicine, he European Society of Endocrinology, and the European Renal Association - European Dialysis and Transplant Association.
Kerns E, Patel S, Cohen DM. Hourly oral sodium chloride for the rapid and predictable treatment of hyponatremia. Clin Nephrol 2013.
Ayus JC, Arieff A, Moritz ML. Hyponatremia in marathon runners. N Engl J Med. 2005;353:427–8.
Hew-Butler T, Ayus JC, Kipps C, et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med. 2008;18:111–21.
Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med. 1987;317:1190–5. One of the few prospective studies evaluating the treatment of symptomatic hyponatremia, it demostrated the safety of using hypertonic saline and that hypoxia, liver disease, and a sodium correction of > 25 mEq/L were risk factors for demyelination.
Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant. 2006;21:70–6.
Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003;145:459–66.
Norenberg MD, Leslie KO, Robertson AS. Association between rise in serum sodium and central pontine myelinolysis. Ann Neurol. 1982;11:128–35.
Ayus JC, Krothapalli RK, Armstrong DL. Rapid correction of severe hyponatremia in the rat: histopathological changes in the brain. Am J Physiol. 1985;248:F711–9.
Gocht A, Colmant HJ. Central pontine and extrapontine myelinolysis: a report of 58 cases. Clin Neuropathol. 1987;6:262–70.
Kallakatta RN, Radhakrishnan A, Fayaz RK, Unnikrishnan JP, Kesavadas C, Sarma SP. Clinical and functional outcome and factors predicting prognosis in osmotic demyelination syndrome (central pontine and/or extrapontine myelinolysis) in 25 patients. J Neurol Neurosurg Psychiatry. 2011;82:326–31.
Brunner JE, Redmond JM, Haggar AM, Kruger DF, Elias SB. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol. 1990;27:61–6.
Verbalis JG, Martinez AJ. Neurological and neuropathological sequelae of correction of chronic hyponatremia. Kidney Int. 1991;39:1274–82.
Soupart A, Penninckx R, Stenuit A, Perier O, Decaux G. Treatment of chronic hyponatremia in rats by intravenous saline: comparison of rate versus magnitude of correction. Kidney Int. 1992;41:1662–7.
Gankam Kengne F, Soupart A, Pochet R, Brion JP, Decaux G. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int. 2009;76:614–21. This study in chronically hyponatremic rats demonstrated that rate of correction is not the determining factor for developing demyelination; rather, it is the overall sustained magnitude of correction exceeding 25 mEq/l.
Lohr JW. Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. Am J Med. 1994;96:408–13.
Goebel HH, Zur PH. Central pontine myelinolysis. A clinical and pathological study of 10 cases. Brain. 1972;95:495–504.
Turnbull J, Lumsden D, Siddiqui A, Lin JP, Lim M. Osmotic demyelination syndrome associated with hypophosphataemia: 2 cases and a review of literature. Acta Paediatr. 2013;102:e164–8.
Leens C, Mukendi R, Foret F, Hacourt A, Devuyst O, Colin IM. Central and extrapontine myelinolysis in a patient in spite of a careful correction of hyponatremia. Clin Nephrol. 2001;55:248–53.
Hagiwara K, Okada Y, Shida N, Yamashita Y. Extensive central and extrapontine myelinolysis in a case of chronic alcoholism without hyponatremia: a case report with analysis of serial MR findings. Intern Med (Tokyo, Japan). 2008;47:431–5.
Koul PA, Khan UH, Jan RA, et al. Osmotic demyelination syndrome following slow correction of hyponatremia: Possible role of hypokalemia. Indian J Crit Care Med. 2013;17:231–3.
Sterns RH, Riggs JE, Schochet Jr SS. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med. 1986;314:1535–42.
Newell KL, Kleinschmidt-DeMasters BK. Central pontine myelinolysis at autopsy; a twelve year retrospective analysis. J Neurol Sci. 1996;142:134–9.
Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med. 1986;314:1529–35.
Wright DG, Laureno R, Victor M. Pontine and extrapontine myelinolysis. Brain. 1979;102:361–85.
Ayus JC, Armstrong DL, Arieff AI. Effects of hypernatraemia in the central nervous system and its therapy in rats and rabbits. J Physiol. 1996;492:243–55.
Soupart A, Penninckx R, Namias B, Stenuit A, Perier O, Decaux G. Brain myelinolysis following hypernatremia in rats. J Neuropathol Exp Neurol. 1996;55:106–13.
Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant. 2003;18:2486–91.
Rafat C, Schortgen F, Gaudry S, et al. Use of desmopressin acetate in severe hyponatremia in the intensive care unit. Clin J Am Soc Nephrol. 2014;9:229–37.
Soupart A, Ngassa M, Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol. 1999;51:383–6.
Albert NM, Nutter B, Forney J, Slifcak E, Tang WH. A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF). J Card Fail. 2013;19:1–9.
Moritz ML. Syndrome of inappropriate antidiuresis and cerebral salt wasting syndrome: are they different and does it matter? Pediatr Nephrol. 2012.
Hantman D, Rossier B, Zohlman R, Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med. 1973;78:870–5.
Mohmand HK, Issa D, Ahmad Z, Cappuccio JD, Kouides RW, Sterns RH. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol. 2007;2:1110–7.
Paulson WD, Bock GH, Nelson AP, Moxey-Mims MM, Crim LM. Hyponatremia in the very young chronic peritoneal dialysis patient. Am J Kidney Dis. 1989;14:196–9.
Claviez A, Thies R, Kleinebudde P, Suttorp M. Microencapsulated NaCl for oral salt-replacement therapy in infants. J Natl Cancer Inst. 1999;91:1513–4.
Decaux G, Waterlot Y, Genette F, Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med. 1981;304:329–30.
Decaux G, Unger J, Brimioulle S, Mockel J. Hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Rapid correction with urea, sodium chloride, and water restriction therapy. Jama. 1982;247:471–4.
Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med. 2001;110:582–4.
Vandergheynst F, Brachet C, Heinrichs C, Decaux G. Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports. Nephron Clin Pract. 2012;120:c168–72.
Soupart A, Penninckx R, Stenuit A, Decaux G. Azotemia (48 h) decreases the risk of brain damage in rats after correction of chronic hyponatremia. Brain Res. 2000;852:167–72.
Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol. 2011;7:151–61.
Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. Am J Kidney Dis. 2010;56:325–37.
Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112. This was a large randomized prospective study demonstrating the safety and efficacy of tolvaptan in correcting euvolemic and hypervolemic hyponatremia with one month of therapy.
Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705–12.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18. This large prospective trial of tolvaptan over a three-year period in patients with autodsomal dominant polycystic kidney disease demonstrated that over 1% of the patient required discontinuation due to liver enzyme abnormalities.
Malhotra I, Gopinath S, Janga KC, Greenberg S, Sharma SK, Tarkovsky R. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans. Case Rep Endocrinol. 2014;2014:807054.
Torres AC, Wickham EP, Biskobing DM. Tolvaptan for the management of syndrome of inappropriate antidiuretic hormone secretion: lessons learned in titration of dose. Endocr Pract. 2011;17:e97–100.
Viktorsdottir O, Indridason OS, Palsson R. Successful treatment of extreme hyponatremia in an anuric patient using continuous venovenous hemodialysis. Blood Purif. 2013;36:274–9.